Clonidine (Clonidine) Patent Expiration, LOE Window & CMS Spending

Clonidine (Clonidine) by Tris: Off-Patent Genericized (AB Competition), 21 AB generics, $68.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTris
FDA Application & PathwayN022499 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors21
2024 CMS Total Public Spend$68.2M
2024 Medicare Part D Spend$60.5M
2024 Medicaid Spend$7.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel